BRCA 1/BRCA 2 Pathogenic/Likely Pathogenic Variant Patients with Breast, Ovarian, and Other Cancers
Authors:
Open Access
- 1 December 2022
- journal article
- research article
- Published by Walter de Gruyter GmbH in Balkan Journal of Medical Genetics
- Vol. 25 (2) , 5-14
Abstract
The demographic and clinical characteristics of patients who have BRCA 1/BRCA 2 pathogenic/likely pathogenic variants may differ from their relatives who had BRCA- related cancer. In this study, we aimed to demonstrate the clinical and demographic findings of patients who had BRCA -related cancer and to assess the differences comparing their relatives who had BRCA -related cancer with breast, genital tract, prostate, and pancreas cancers as well. The results of sequencing analysis of 200 cancer patients (190 women, 10 men) who have been directed to genetic counseling with an indication of BRCA1/BRCA2 testing from different regions across 9 medical oncology centers were retrospectively analyzed. A total of 200 consecutive cancer patients who harbored the BRCA1/BRCA2 pathogenic/likely pathogenic variant (130 (65%) patients harbored BRCA 1 pathogenic/likely pathogenic variant, and 70 harbored BRCA 2 pathogenic/likely pathogenic variant) were included. Of these, 64.0% had breast cancer (43.8% of them had the triple-negative disease, and about 2.3% had only the HER-2 mutant), 31.5% had genital cancers (92.1% of them had ovarian cancer, 3.2% had endometrium, and 1.6% had peritoneum cancer as the primary site and mostly serous adenocarcinoma was the most common histopathology and 14.3% of the patients had endometrioid adenocarcinoma), 3.5% had prostate (median time from metastasis to castration-resistant status was 28 months) and 1.0% had pancreas cancer. Newly diagnosed cancer (breast and ovary) patients who had BRCA 1/BRCA 2 pathogenic/ likely pathogenic variant were younger than their previous cancer diagnosed (breast, ovary, and pancreas) parents who harbored BRCA pathogenic/likely pathogenic variant. We suggest that the genetic screening of BRCA 1/ BRCA 2 pathogenic/likely pathogenic variant is needed as a routine screening for those with a personal or family history of breast, ovarian, tubal, or peritoneal cancer. In addition, once BRCA 1 or BRCA 2 germline pathogenic variant has been identified in a family, testing of at-risk next-generation relatives earlier can identify those family members who also have the familial pathogenic variant, and thus need increased surveillance.Keywords
This publication has 39 references indexed in Scilit:
- Association Between BRCA1 and BRCA2 Mutations and Survival in Women With Invasive Epithelial Ovarian CancerJAMA, 2012
- Characteristics of Triple-Negative Breast Cancer in Patients With a BRCA1 Mutation: Results From a Population-Based Study of Young WomenJournal of Clinical Oncology, 2011
- Association of BRCA1 and BRCA2 Mutations With Survival, Chemotherapy Sensitivity, and Gene Mutator Phenotype in Patients With Ovarian CancerJAMA, 2011
- YKL-40 tissue expression and plasma levels in patients with ovarian cancerBMC Cancer, 2009
- Clinical and Pathologic Characteristics of Patients With BRCA-Positive and BRCA-Negative Breast CancerJournal of Clinical Oncology, 2008
- Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 StudyJournal of Clinical Oncology, 2008
- Effect of BRCA1/2 Mutations on Long-Term Survival of Patients With Invasive Ovarian Cancer: The National Israeli Study of Ovarian CancerJournal of Clinical Oncology, 2008
- Meta-Analysis of BRCA1 and BRCA2 PenetranceJournal of Clinical Oncology, 2007
- Pathology of Ovarian Cancers in BRCA1 and BRCA2 CarriersClinical Cancer Research, 2004
- Cancer Risks in BRCA2 Mutation CarriersJNCI: Journal of the National Cancer Institute, 1999